The EU biosimilar framework – experience to date. The EU regulatory network and emerging trends – a review of quality, safety and clinical development programmes

Category: Review Article
Author(s): , , , ,
Visits: 88 total, 1 today
Keywords: biosimilars, clinical development programmes, EMA, EPARs, regulatory, safety

Author byline as per print journal: Marta Zuccarelli1, PharmD; Benjamin Micallef1, PharmD; Mark Cilia1, PharmD; Anthony Serracino-Inglott1, 2, PharmD; Professor John-Joseph Borg1, 3, PhD

Introduction/Study Objectives: The development of biosimilars is challenging due to the complexity of the active substances as well as the strict regulatory requirements to show similarity with a reference medicinal product. This review aims to describe the regulatory experience of approving biosimilars in the European Union (EU) within the EU framework, identify emerging trends in the EU regulatory pathway when approving biosimilars and discuss where the EU biosimilar framework is heading to.
Methods: Marketing authorisation applications (MAAs) submitted up to 2019 were retrieved from the public domain. The European public assessment report database was searched for approved biosimilars and clinical development programmes of biosimilars belonging to the same class were reviewed. In order to observe if biosimilars released onto the market increased safety concerns, we compared disproportionate adverse event reports pre- and post-licensure.
Results: Up to December 2019, 90 MAAs were submitted and 53 biosimilars are approved for 14 different biologicals. Total number of clinical trials (both phase I and III) steadily goes up driven by an increase number of approvals in later years, while the average number of both phase I and III goes down over time with some with Pegfilgrastim biosimilars being approved without conducting any phase III clinical trials. No new safety concerns were identified from the analysis of disproportionate adverse event reports.
Discussion: Clinical development programmes of biosimilars and the requirements set for biosimilars approval are changing over time. Biosimilars approved seem to be as safe as the reference products when approved based on stringent regulatory requirements.
Conclusion: Regulation of biosimilars is progressing as more knowledge is gained.

 

Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.

Go Back Print

Leave a Reply